Markers for early detection of cancer: Statistical guidelines for nestedcase-control studies

BMC Medical Research Methodology

Volumn 2, Issue , 2002, Pages 1-8

  Baker, Stuart G ^a   Kramer, Barnett S ^b   Srivastava, Sudhir ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CASE CONTROL STUDY; EARLY DIAGNOSIS; PRACTICE GUIDELINE; STATISTICAL CONCEPTS; STATISTICS; EPIDEMIOLOGY; HUMAN; LABORATORY DIAGNOSIS; METHODOLOGY; NEOPLASM; REPRODUCIBILITY; SAMPLE SIZE; STANDARD;

BIOLOGICAL MARKER;

BIAS (EPIDEMIOLOGY); BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SAMPLE SIZE; SELECTION BIAS; STATISTICS;

EID: 34248352185     PISSN: 14712288     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2288-2-4     Document Type: Article

References (22)

1. Xu Y, Shen ZZ, Wiper DW, Wu MZ, Morton RE, Elson P, Kennedy AW, Belinson J, Markman M, Casey G: Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998, 280:719-723
2. Signorello LB, Brismar K, Bergstrom R, Andersson SO, Wolk A, Trichopoulos D, Adami HO: Insulin-like growth factor-binding protein-1 and prostate cancer. Journal of the National Cancer Institute 1999, 91:1965
3. You WC, Blot WJ, Zhang L, Kneller RW, Li JY, Jin ML, Chang YS, Zeng XR, Zhao L, Fraumeni JF, Xu GW, Samloff MI: Serum pepsinogens in relation to precancerous gastric lesions in a population at high risk for gastric cancer. Cancer Epidemiology, Biomarkers, and Prevention 1993, 2:113-117
4. Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MAS, Narod SA: Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate specific antigen. Journal of Clinical Oncology 2000, 18:1036-1042
5. Langholz B: Case-control study, nested. In The Encyclopedia of Biostatistics, Chichester: 1998514-519
6. Pepe MS, Etzioni R, Feng S, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y: Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute 2001, 93:1054-1061
7. The ATBC Cancer Prevention Study Group: The Alpha-Tocopherol, Beta-Carotene Lung Cancer Prevention Study: Design, methods, participant characteristics, and compliance. Annals of Epidemiology 1994, 4:1-10
8. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL Jr, Valanis B, Williams JH, Barhart S, Cherniack MG, Brodkin CA, Hammar S: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. Journal of the National Cancer Institute 1996, 88:1550-9
9. Lillienfeld AM: Some limitations and problems of screening for cancer. Cancer 1974, 35(Suppl):1720-1724
10. Baker SG, Pinsky PF: A proposed design and analysis for comparing digital and analog mammography: special receiver-operating characteristic methods for cancer screening. Journal of the American Statistical Association 2001, 96:421-428
11. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK: Prostate-cancer screening-what we know and what we need to know. Annals of Internal Medicine 1993, 119:914-923
12. Shaprio S, Venet W, Strax P, Venet L: Periodic Screening for Breast Cancer, The Health Insurance Plan Project and Its Sequelae, 1963-1986, Baltimore, Johns Hopkins University Press.
13. Emir B, Wieand S, Su JQ, Cha S: Analysis of repeated markers used to predict progression of cancer. Statistics in Medicine 1998, 17:2563-78
14. Swets JA: Measuring the accuracy of diagnostic systems. Science 1988, 240:1285-1293
15. Mok SC, Chao J, Skates S, Wong K, Yiu GK, Muto MG, Berkowitz RS, Cramer DW: Prostasin, a potential serum marker for ovarian cancer: Identification through microarray technology. Journal of the National Cancer Institute 2001, 93:1458-64
16. Baker SG: Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics 2000, 56:1082-1087
17. Gail MH, Muenz L, McIntire KR, Radovich B, Braunstein G, Brown PR, Deftos L, Dnistrian A, Dunsmore M, Elashoff R, Geller N, Go VLW, Hirji K, Klauber MR, Pee D, Petroni G, Schartz M, Wolfsen AR: Multiple markers for lung cancer diagnosis: validation of models for advanced lung cancer. Journal of the National Cancer Institute 1986, 76:805-826
18. Hastie T: Neural networks. In The Encyclopedia of Biostatistics, Chichester: 19982986-2989
19. Morell CH, Pearson JD, Carter HB, Brant LJ: Estimating unknown transition times using a piecewise nonlinear mixed-effects model in men with prostate cancer. Journal of the American Statistical Association 1995, 90:45-53
20. Baker SG, Tockman MS: Evaluating serial observations of pre-cancerous lesions for further study as a trigger for early intervention. Statistics in Medicine.
21. Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA: Modelling strategies for improved prognostic prediction. Statistics in Medicine 1984, 3:143-152
22. Steyerberg EW, Harrell FE Jr, Borsboom GJJM, Eijkemans MJC, Vergouwe Y, Habbema JDF: Internal validation of predictive models; Efficiency of some procedures for logistic regression. Journal of Clinical Epidemiology 2001, 54:774-781